We report a 50-year-old man, diagnosed with advanced renal cell carcinoma (RCC), who was treated with sunitinib for 7 months until progression. Sorafenib was started as second-line treatment 2 weeks later. Within 10 days after initiation of sorafenib treatment, the patient developed skin rash with erythema, influenza-like symptoms, hypertension, generalized edema and oliguria. Renal failure with a serum creatinine level of 306 lmol/l, proteinuria of 20 g/24 h and hematuria of 150 red blood cells (RBC)/ll was found. Before start of treatment with sorafenib, renal function was normal and similar to before start of sunitinib treatment [estimated glomerular filtration rate (eGFR) using modification of diet in renal disease (MDRD) formula >90 ml/min] with no signs of proteinuria. Treatment with sorafenib was terminated, a kidney biopsy was obtained and the patient was treated with high-dose corticosteroids and angiotensin-converting enzyme inhibitors, in order to lower proteinuria. Serum creatinine levels decreased after initiation of corticosteroids and normalized within 1 month; eGFR using MDRD recovered to 80 ml/min. Clinical symptoms of a nephrotic syndrome dissolved, but proteinuria remained 3.8 g/ day, while hematuria almost completely recovered to 10 RBC/ll.
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The renal biopsy during treatment with sorafenib showed mild acute thrombotic microangiopathy (TMA), while there were no abnormalities seen in the non-neoplastic areas of the renal biopsy obtained 8 months earlier when advanced RCC was diagnosed ( Figure 1A ). Light microscopy examination revealed mesangiolysis, dilatation of capillary loops and stasis of erythrocytes ( Figure 1B ) and ultrastructural subendothelial widening with fluffy proteinaceous material ( Figure 1E ). A subcortical area in the kidney biopsy contained limited interstitial inflammation ( Figure 1C ). There were no deposits or glomerular basement membrane abnormalities ( Figure 1D ) but total foot process effacement in podocytes consistent with minimal change disease (MCD) ( Figure 1E ). On the basis of these findings, we concluded that sorafenib induced renal failure and a nephrotic syndrome due to a unique combination of acute TMA and MCD. It is unclear whether the switch from sunitinib to sorafenib treatment might have played a role in the cause of the toxicity in this patient.
Sorafenib is an antiangiogenic tyrosine kinase inhibitor which inhibits, among other tyrosine kinases, vascular endothelial growth factor receptors (VEGFRs) [1] . Vascular endothelial growth factor (VEGF) not only is important in pathologic angiogenesis but also plays a role in physiological processes such as the coagulation cascade and blood pressure [2] . In the kidney, VEGF may play an important role in development and maintenance of glomerular endothelium. Glomerular endothelial cells express VEGFRs, and VEGF is produced by podocytes [3] .
No proteinuria or renal impairment was observed in early clinical trials with sorafenib. Just lately, sunitinib and sorafenib have been reported to cause proteinuria up to 10.4 g/day [4] and sunitinib and bevacizumab to cause TMA [5, 6] . The etiology of renal TMA is not exactly known, but a disturbance of the homeostasis between vascular cells and the coagulation cascade is expected to be of importance. Angiogenesis inhibitors may interfere in this homeostasis by disturbing the platelet-endothelial homeostasis, causing endothelial cell apoptosis, increased activity of tissue factor, platelet activation and subsequent thrombosis [2] .
In conclusion, we report for the first time that sorafenib treatment caused a unique combination of acute TMA and MCD resulting in renal failure and nephrotic syndrome. Further studies are warranted to determine the letters to the editor Annals of Oncology
